← Treatments
CHICOVERY

Treatment-resistant psychiatry and neuromodulation

For a small group of patients with extremely treatment-resistant OCD, depression or other severe psychiatric disorders, China is investigating advanced neuromodulation such as DBS and focused ultrasound. This is not a pathway for routine first-line psychiatric care.

Evidence status: Highly specialised / partly experimental

What is the medical problem?

Some patients remain severely impaired despite multiple adequate medication trials, specialised psychotherapy, augmentation, ECT, TMS or other standard treatment steps. Remaining options are limited for this group.

Which options are being considered?

  • specialist reassessment of diagnosis and previous treatments
  • DBS in very strictly selected treatment-resistant OCD and other investigated indications
  • dual-target DBS in research or highly specialised settings
  • reassessment of TMS/ECT/ketamine
  • low-intensity transcranial focused ultrasound only in research or experimental settings

What could a treatment pathway look like?

A complete psychiatric record must show that recognised treatment steps were carried out correctly and for sufficient duration. This is followed by multidisciplinary assessment by psychiatry, neurology and functional neurosurgery. Invasive neuromodulation is considered only for exceptional indications.

What do we know about effectiveness?

DBS has a limited but serious evidence base for severe treatment-resistant OCD and is used internationally only in highly selected patients. For depression, schizophrenia, bipolar disorder, addiction and tFUS, various applications remain experimental or research-based.

Important selection considerations

DBS is brain surgery and carries neurological, infectious and psychiatric risks. This pathway should be discussed only after high-quality standard treatment has demonstrably been exhausted and independent specialist assessment has taken place.

Medical selection before travel

The options described are not a guarantee of treatment. Availability and suitability depend on diagnosis, indication, evidence level, individual risks and assessment by the treating medical team. Experimental care is identified as such.

Would you like to know whether a pathway could be medically appropriate?

A treatment journey always begins with an assessment of the diagnosis, medical history, previous treatments, medication, risks and the specific treatment objective.

Start medical intake